Vicarious Surgical (RBOT) director option: 5,335 shares at $7.61
Donald F. Tang, a director of Vicarious Surgical Inc. (ticker: RBOT), reported receipt of a stock option on 06/27/2025.
Rhea-AI Filing Summary
Donald F. Tang, a director of Vicarious Surgical Inc. (ticker: RBOT), reported receipt of a stock option on 06/27/2025. The option covers 5,335 underlying shares of Class A common stock with an exercise price of $7.61. The filing states all shares underlying the option will vest on June 27, 2026 or one day prior to the issuer's next annual meeting, whichever is earlier, provided the reporting person remains in service through the vesting date. The Form 4 shows the report was signed by an attorney-in-fact, Erin Checka, on 08/11/2025.
Positive
- Director received a stock option grant covering 5,335 underlying Class A shares, as reported on the Form 4
- Exercise price disclosed: $7.61 per share, providing clear terms in the filing
- Vesting schedule provided: full vesting on June 27, 2026, or one day prior to the issuer's next annual meeting, subject to continued service
Negative
- None.
Insights
TL;DR: Routine director equity award; limited immediate cash impact, potential future dilution upon exercise.
The reported transaction is a time-based stock option grant to a director for 5,335 shares at a $7.61 exercise price, documented on a Form 4 filed for RBOT. As a standard compensation tool, this option creates a potential future obligation only if exercised; there is no cash proceeds or immediate change to revenue or earnings reported in this filing. Without company-wide share counts or prior insider holdings in this filing, the absolute dilutive effect cannot be quantified from the document alone. The vesting schedule (by 06/27/2026 or one day prior to the next annual meeting) ties value to continued service, which is a common governance practice.
TL;DR: Grant follows typical director compensation patterns; vesting condition aligns with service and shareholder meeting timing.
The Form 4 indicates the option vests within roughly one year, conditioned on continued service, which aligns director incentives with near-term company performance and governance milestones. The filing was executed by an attorney-in-fact, showing standard administrative handling. The document does not disclose grant authorization details, board approval context, or how this award fits within the overall compensation program, so governance implications are limited to the disclosed vesting terms and award mechanics.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 5,335 | $0.00 | $0.00 |
Footnotes (1)
- F1. All of the shares underlying this option will vest on June 27, 2026, or one day prior to the Issuer's next Annual Meeting of Shareholders, whichever is earlier, subject to the Reporting Person's continued service through the applicable vesting date.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What transaction did Donald F. Tang report on the RBOT Form 4?
When do the options vest according to the filing?
What is the relationship of the reporting person to Vicarious Surgical (RBOT)?
Who signed the Form 4 and when was it signed?
Does the filing show an expiration or other date for the derivative instrument?
AI-generated analysis. How Rhea-AI works. Not financial advice.